Dexcom Stelo Glucose Biosensor

Stelo is Dexcom's answer to a question a lot of health-curious people have been asking for years: what if you could just buy a continuous glucose monitor? No prescription, no clinic visit, no insurance wrangling. At $99 for a month's supply of two sensors, it lands at a price that's an impulse purchase for some and a considered one for most — and crucially, it's HSA/FSA eligible, which softens the blow.

The target audience here is narrow and clearly drawn. This is for adults who don't use insulin: people with prediabetes, people managing type 2 diabetes through diet and oral medication, and the broad category of metabolically curious folks who want to see what a bagel actually does to them. If you use insulin, have problematic hypoglycemia, or are on dialysis, Stelo is explicitly not built for you, and that's a limitation worth taking seriously rather than working around.

Physically it's an unfussy proposition — an all-in-one sensor and transmitter applied to the back of the upper arm with a spring-loaded applicator, an overpatch to keep it there, and 15 days of wear before you swap. Thirty minutes of warm-up and you're reading. The 8-foot water resistance rating means showering and swimming aren't a consideration, which matters more than it sounds when you're wearing something for a fortnight.

What Stelo gets right is the fundamentals. A claimed MARD of 8.3% is respectable for a consumer device, and Dexcom's pedigree in this category is not nothing. Fifteen-day wear is at the generous end, meaning two sensors genuinely cover a month with a little slack. The app is free, works on both platforms, and pushes data out to Apple Health, Apple Watch, Oura and a handful of third-party health platforms, so your glucose data isn't stranded in a silo.

Where it gets more complicated is what Dexcom has deliberately left out. There are no urgent low-glucose alarms — the safety-critical feature that defines prescription CGMs. That's a reasonable design decision for a non-insulin-using audience, but it means Stelo should be read as an insight tool, not a warning system. It won't diagnose diabetes, shouldn't replace lab work, and isn't a basis for changing your own medication.

The app itself is comparatively spartan next to subscription platforms like Levels or Nutrisense. You get real-time values, trend arrows, weekly pattern reports, time-in-range scoring, and more recently GenAI insights and photo-based meal logging. What you don't get is meal scoring, coaching or deep analytics. For some buyers that's a feature — the price is lower precisely because you're not paying for a nutrition service. For others it will feel like being handed a lot of numbers and no interpreter.

One genuine annoyance: the sources we have disagree on how often the thing actually reads. One puts it at every five minutes, another describes a 15-minute display update. Those are meaningfully different experiences if you're trying to catch a post-meal spike, and we'd want that nailed down before recommending Stelo to anyone chasing granular real-time data. A few other details — the bundled dietitian video calls in particular — come from a single source and we'd treat them as unconfirmed.

On cost, the subscription tiers work out to roughly $1,057–$1,201 a year depending on how much you commit to, which is a meaningful ongoing expense for what is, for most users, an educational rather than clinical tool. Many people will get most of the value from a month or two of wear and then stop, and the lack of a minimum commitment makes that a perfectly sensible way to use it.

Stelo earns its rating by doing something important — removing the prescription gate from CGM — and doing the hardware part well. It loses ground on app depth, the absent alarms, and a spec sheet with an unresolved contradiction at its centre.